XRAY — Stock Film
STOCK FILMSCENE 1/11XRAY · $10.46
Stock Expert AI presents
XRAY
DENTSPLY SIRONA Inc
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
DENTSPLY SIRONA Inc. What it actually does.

Manufactures and sells dental treatment centers and imaging equipment. Provides CAD/CAM technologies for digital dental procedures. Now — the numbers.

on the stock market since 1987
14K employees
$2.1B market value
WHERE DOES THE MONEY COME FROM?
59%Technologies and Equipment
Technologies and EquipmentConsumables 41%
59% of all revenue comes from a single line: Technologies and Equipment.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$3.7B
The loss that same year:
$598M
For every $1 it earns, the company spends $1.2.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

In the vault right now:
$326M
DEBT: $2.5B
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

THE PRICE TAG
MARKET VALUE / ANNUAL SALES
0.6×

This company is not turning a profit, so the market is pricing its sales instead: 0.6× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 74% of them.

Analysts' average target sits 34% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
72
strong

Clearly above the class average — a step short of the very top.

FINANCIAL STRENGTH
19
very weak

Clearly below the class average.

VALUATION
74
strong

Clearly above the class average — a step short of the very top.

GROWTH
48
weak

Clearly below the class average.

PRICE MOMENTUM
44
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 82% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 66 buys and 14 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.64 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/2
The losses continue

A loss of $598M against $3.7B in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
28 / 100 · MoonshotScore

On our five-subject report card, XRAY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: XRAY’s sales are going backwards, and it closed last year at a loss. The road back runs through both.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 11, 2026 · stockexpertai.com · Stock Film